$2.54 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 98 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVNC | New | REVANCE THERAPEUTICS INC | $35,750,000 | – | 1,000,000 | +100.0% | 1.41% | – |
| DVA | New | DAVITA INC | $30,706,000 | – | 425,000 | +100.0% | 1.21% | – |
| ANTM | New | ANTHEM INC | $29,251,000 | – | 130,000 | +100.0% | 1.15% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $24,179,000 | – | 741,016 | +100.0% | 0.95% | – |
| EVHC | New | ENVISION HEALTHCARE CORP | $23,363,000 | – | 676,000 | +100.0% | 0.92% | – |
| New | DEPOMED INCnote 2.500% 9/0 | $22,776,000 | – | 27,019,000 | +100.0% | 0.90% | – | |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $16,913,000 | – | 582,010 | +100.0% | 0.67% | – |
| UHS | New | UNIVERSAL HLTH SVCS INCcl b | $14,962,000 | – | 132,000 | +100.0% | 0.59% | – |
| BLUE | New | BLUEBIRD BIO INC | $14,248,000 | – | 80,000 | +100.0% | 0.56% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $11,132,000 | – | 513,000 | +100.0% | 0.44% | – |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $10,530,000 | – | 145,000 | +100.0% | 0.41% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $9,880,000 | – | 450,728 | +100.0% | 0.39% | – |
| RGNX | New | REGENXBIO INC | $8,522,000 | – | 256,300 | +100.0% | 0.34% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $6,844,000 | – | 375,000 | +100.0% | 0.27% | – |
| ALNA | New | ALLENA PHARMACEUTICALS INC | $6,087,000 | – | 605,100 | +100.0% | 0.24% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $4,680,000 | – | 225,000 | +100.0% | 0.18% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $4,185,000 | – | 300,000 | +100.0% | 0.16% | – |
| IFRX | New | INFLARX NV | $3,666,000 | – | 175,000 | +100.0% | 0.14% | – |
| TSRO | New | TESARO INC | $3,555,000 | – | 42,893 | +100.0% | 0.14% | – |
| PFNX | New | PFENEX INC | $2,208,000 | – | 830,216 | +100.0% | 0.09% | – |
| ASNS | New | ARSANIS INC | $1,679,000 | – | 131,548 | +100.0% | 0.07% | – |
| KIDS | New | ORTHOPEDIATRICS CORP | $1,118,000 | – | 58,247 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.